Cargando…
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during HCC treatment. Lenvatinib has been a...
Autores principales: | Shi, Tingting, Iwama, Hisakazu, Fujita, Koji, Kobara, Hideki, Nishiyama, Noriko, Fujihara, Shintaro, Goda, Yasuhiro, Yoneyama, Hirohito, Morishita, Asahiro, Tani, Joji, Yamada, Mari, Nakahara, Mai, Takuma, Kei, Masaki, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657692/ https://www.ncbi.nlm.nih.gov/pubmed/34884875 http://dx.doi.org/10.3390/ijms222313071 |
Ejemplares similares
-
Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022) -
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020) -
MicroRNA profiles in various hepatocellular carcinoma cell lines
por: Morishita, Asahiro, et al.
Publicado: (2016) -
Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022) -
Submucosal tunneling techniques: current perspectives
por: Kobara, Hideki, et al.
Publicado: (2014)